Kairos Pharma (KAPA) Institutional Ownership $0.96 -0.01 (-1.32%) As of 08/7/2025 04:10 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartHeadlinesOwnershipSEC FilingsBuy This Stock Institutional Ownership Changes (13F Filings) for Kairos Pharma (NYSEAMERICAN:KAPA)Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$1.31MNumber ofInstitutional Sellers(last 12 months)0 Get KAPA Insider Trade Alerts Want to know when executives and insiders are buying or selling Kairos Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Kairos Pharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/15/2025Armistice Capital LLC1,404,000$1.31M0.0%N/A10.248% (Data available from 1/1/2016 forward) KAPA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of KAPA shares? During the previous two years, the following institutional investors and hedge funds held shares of Kairos Pharma shares: Armistice Capital LLC ($1.31M).Learn more on Kairos Pharma's institutional investors. Which institutional investors have been buying Kairos Pharma's stock? The following institutional investors have purchased Kairos Pharma's stock in the last 24 months: Armistice Capital LLC ($1.40M). How much institutional buying is happening at Kairos Pharma? Institutional investors have bought a total of 1,404,000 shares in the last 24 months. This purchase volume represents approximately $1.31M in transactions. Related Companies PMV Pharmaceuticals Institutional Ownership Context Therapeutics Institutional Ownership Artiva Biotherapeutics Institutional Ownership Atara Biotherapeutics Institutional Ownership Pyxis Oncology Institutional Ownership CervoMed Institutional Ownership Genenta Science Institutional Ownership MediciNova Institutional Ownership Quantum Biopharma Institutional Ownership Assertio Institutional Ownership This page (NYSEAMERICAN:KAPA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kairos Pharma, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kairos Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
